<DOC>
	<DOCNO>NCT02970630</DOCNO>
	<brief_summary>Prospective , single-arm , open-label , multicentre study principal aim estimate tacrolimus pharmacokinetic parameter elderly de-novo kidney transplant recipient ECD ( Extended Criteria Donor ) kidney graft treat Envarsus® prolong release tablet combination everolimus tablet .</brief_summary>
	<brief_title>Envarsus® Once Daily With Everolimus Elderly Kidney Transplant Recipients : Pharmacokinetic Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Subject 's write informed consent obtain prior transplant intervention prior studyrelated procedure ; 2 . Caucasian male female subject age 60 old receive primary secondary single dual renal transplant blood group compatible decease donor ; 3 . Patients plan receive renal allograft Extended Criteria Donor ( ECD ) ; 4 . Patients capable understanding purpose risk study , give write informed consent willing participate comply study ; 5 . Patients low standard immunological risk , PRA ( Panel Reactive Antibody ) ≤ 20 % ( PRA test accord centre 's practice ) ; 6 . Body Mass Index ( BMI ) 15 35 kg/m2 extreme inclusive ; 7 . Women must postmenopausal ( physiologic menopause define `` 12 consecutive month amenorrhea '' ) permanently sterilize ( e.g . tubal occlusion , hysterectomy bilateral salpingectomy ) enrol study . 1 . Recipients transplant organ single dual kidney ; 2 . Patients unable unwilling provide inform consent ; 3 . Male subject females partner childbearing potential UNLESS partner willing use reliable method contraception ( see detail ) time first dose administration 8 week last dose study drug . Male subject partner nonchildbearing potential require use contraception . Reliable method contraception male subject partner childbearing potential must one following : 1 . Placement intrauterine device intrauterine system 2 . Hormonal contraception ( implantable , patch , oral ) 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical vaults/caps ) spermicidal foam/gel/film/cream/suppository . 4 . Male sterilization ( appropriate postvasectomy documentation absence sperm ejaculate `` True abstinence '' acceptable line prefer usual lifestyle subject . 4 . Recipients bone marrow stem cell transplant ; 5 . Recipients kidney cardiac death donor ; 6 . Recipients kidney ABO ( 0 , A blood cell type ) incompatible donor ; 7 . Recipients pretransplant donor specific antiHLA ( Human leukocyte antigen antibody ) ( DSA ) lose first kidney transplant acute rejection ; 8 . Recipients kidney anticipate cold ischemia time ≥ 24 hour ; 9 . Recipients positive Hepatitis C virus ( HCVRNA positive ) and/or Hepatitis B Virus ( HBVDNA HBsAg positive ) ; 10 . Recipients positive Human Immunodeficiency Virus ( HIVAb positive ) ; 11 . Patients current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully ; 12 . Patients uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective ; 13 . Patients severe diarrhoea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption study drug ; 14 . Patients white blood cell count ≤ 2.8x109/L unless absolute neutrophil count ( ANC ) ≥ 1.0x109/L ; 15 . Patients platelet count ≤ 50.0x109/L ; 16 . Patients aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) enzyme level &gt; 3 time upper limit normal 30 day prior transplant procedure ; 17 . Patients treat investigational agent three month prior enrolment ; 18 . Patients receive investigational new drug , participate clinical study within last 8 week ; 19 . Patient plan receive induction therapy different rabbit ATG ( Antithymocyte globulin ) alone patient start rabbit ATG induction therapy transplant ; 20 . Patients already immunosuppressive drug day transplantation , except ATG per protocol ; 21 . Patients plan receive therapy immunosuppressive agent prescribe study ; 22 . Patients know hypersensitivity corticosteroid , tacrolimus everolimus sirolimus excipients present study drug formulation ; 23 . Patients hypersensitivity macrolides ; 24 . Patients form substance abuse , psychiatric disorder condition , opinion Investigator , may invalidate communication Investigator ; 25 . Subjects unlikely comply study protocol unable understand nature scope study also possible benefit unwanted effect study treatment ; 26 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prophylaxis</keyword>
</DOC>